5 High Growth UK Stocks to Buy

2. Autolus Therapeutics plc (NASDAQ:AUTL)

Q/Q Sales Growth: N/A

Number of Hedge Fund Holders in Q4 2022: 18

Autolus Therapeutics plc (NASDAQ:AUTL) is a biotechnology firm developing treatments for cancers such as myeloma and neuroblastoma. The firm is based in London, United Kingdom.

Autolus Therapeutics plc (NASDAQ:AUTL)’s third fiscal quarter ending in September 2022 saw it post $2.3 million in revenue, yet since the year ago quarter’s revenue was $0, there is no growth percentage for this. 18 of the 943 hedge funds part of our Q4 2022 survey had bought the firm’s shares.

Autolus Therapeutics plc (NASDAQ:AUTL)’s largest investor is David Kroin’s Deep Track Capital which owns 15 million shares that are worth $28.5 million.

Follow Autolus Therapeutics Plc (NASDAQ:AUTL)